Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 8/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16209027 | 0.90 | CSF1R (0.35) | CSF1R | |
| SCHEMBL5649517 | 0.87 | CSF1R (0.34) | CSF1R | |
| SCHEMBL16208942 | 0.86 | CSF1R (0.36) | CSF1RALDH1A1 | |
| SCHEMBL3916494 | 0.86 | CSF1R (0.41) | CSF1RALDH1A1 | |
| SCHEMBL16209220 | 0.83 | CSF1R (0.37) | CSF1R | |
| SCHEMBL3165594 | 0.83 | CSF1R (0.40) | CSF1R | |
| SCHEMBL3906113 | 0.81 | CSF1R (0.38) | CSF1RALDH1A1 | |
| SCHEMBL16209318 | 0.81 | CSF1R (0.36) | CSF1RALDH1A1 | |
| SCHEMBL16208943 | 0.81 | CSF1R (0.36) | CSF1R | |
| SCHEMBL16209104 | 0.79 | CSF1R (0.35) | CSF1RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403804-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-02 | — | — | US | disclosed |
| US-20140329815-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-06 | — | — | US | disclosed |
| US-8815867-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-26 | — | — | US | disclosed |
| EP-2016058-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007124322-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249608-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249608-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885ACKR3 1902/4885CYP2C9 1815/4885 |
| US-20140329815-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885ACKR3 1902/4885CYP2C9 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.